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1. Introduction 
Parkinson’s disease (PD) is the second most common progressive neurodegenerative 
disorder second to Alzheimer’s disease, affecting 1-2% of individuals over 60 years of age, 
with a risk that increases with age. 
Its phenotypic complexity, characterized by motor (resting tremor, bradikinesia, rigidity and 
postural instability) and non-motor (autonomic dysfunction and cognitive impairment) 
symptoms lead to the description of this disorder as a syndrome rather than a monolithic 
disease. Genetic research in the past 10 years, in particular  mapping and cloning of genes 
which cause the inherited form of the disease, has shown that “Parkinson syndrome” is not 
one disease entity but rather an atherogeneous group of disorders that are associated with a 
spectrum of clinical and pathological changes. It is believed to be caused by the interaction 
of environmental factors and genetic variants acting on the stage of an aging brain. 
There is a growing body of evidence that genetic risk factors are of major importance in PD. 
So far 16 loci have been identified involved in PD. 
PD can be referred mostly as sporadic (90-95%) and to a lesser extent as familial (5%) 
Familial PD is caused by very rare highly age penetrant mutations, inherited in a Mendelian 
way (autosomal recessive or dominant). The biological effect of these mutations is sufficient 
alone for the development of the disease. 
Sporadic PD is a complex multifactorial disease in which very common genetic variants play 
a very modest role singularly while taken all together, interacting with other genes and 
environmental factors, they can exert an important cumulative effect leading to the 
development of the disease. 
In the last decade pathogenic mutations in five genes (SNCA, LRRK2, PRKN, DJ-1 and 
PINK1) have been linked to familial PD. Recently genome wide association studies, GWAS, 
across different populations identified other 6 loci involved in the sporadic disease (MAPT, 
SNCA, HLA-DRB5, BST1, GAK and LRRK2). Finally a meta-analysis of the 5 previous GWAS 
discovered 5 new loci in association with the idiopatic disease (ACMSD, STK39, 
MCCC1/LAMP3, SYT11 and CCDC62/HIP1R) (International Parkinson Disease Genomics 
Consortium, 2011) 
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2. Familial PD  
Familial PD is monogenic and caused by rare highly age-dependent penetrant mutations, 
which follow a Mendelial pattern of inheritance (autosomal dominant or recessive).  
 
 
 
 
 
Fig. 1. The hyperbole descrives the relationship between the allelic frequency and the 
biological effect in the complex traits. The monogenic Mendelian forms are responsible for 
the familial Parkinson’s disease, in which rare mutations can cause, independently from 
other factors, the disease, with a probability which increases with the age, due to the 
penetrance. The complex, poligenic, sporadic form is  linked to  risk factors which can be 
very common in the population but unable alone to determine the disease without 
interacting with other factors like genetic or environmental ones. Mutations in several 
familial (Mendelian) genes have been identified as causal factors for PD. Mutations in 
LRRK2, SNCA, MAPT, UCHL1 determine the autosomal dominant disease while the 
recessive form is caused by mutations in PARKIN, PINK1, DJ-1 and to a lesser extent FBXO7 
and ATP 13A2. Common variants in SNCA, LRRK2, MAPT, HLA, contribute to the 
development of the idiopatic disease. High-risk factors for the sporadic disease are 
mutations in GBA and LRRK2 genes, especially among isolated populations like Ashkenazi 
Jews. Interestingly rare highly penetrant dominant mutations in SNCA, LRRK2 and MAPT 
cause familial parkinsonian syndromes and common variants at the same loci increase 
susceptibility for PD in the general population. 
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The classic approaches of linkage analysis and positional cloning have been very successful 
strategies to identify genes causing the autosomal-dominantly inherited diseases including 
the major forms of familial PD. 
This strategy relies on the availability of large and clinically well-characterized families, 
usually with at least 8–10 affected family members. By studying the co-segregation of 
genetic (DNA)markers, the genetic locus of the disease-causing gene in a given family can 
be narrowed down to a region of several million base pairs (megabases, Mb) of DNA. The 
statistical method to estimate the likelihood that a particular set of neighbouring DNA 
markers (a so-called haplotype) are co-inherited with a disease gene as a result of its 
physical proximity on the chromosome (i.e. that DNA markers and disease gene are 
‘linked’) is called linkage analysis. The most important prerequisite for this type of study, 
in addition to the availability of sufficiently large families, is the unequivocal 
classification of affected and unaffected family members. Erroneous classification, which 
in many age-related complex diseases is a real possibility, will lead to false linkage results 
(Gasser, 2008). When a disease locus is identified with sufficient confidence (a so-called 
lod score of >3 is equivalent to a genome-wide p.value of 0.05 and is considered to be 
significant evidence), all the genes in the identified region have to be sequenced and 
analysed for potentially disease-causing mutations. Of course, not all of the identified 
sequence variants in a linked region are pathogenic. This means that either the 
demonstration of mutations in several independent families co-segregating with a disease 
is necessary (amounting in effect to a replication of the initial finding) or the careful 
functional studies in model systems are required to prove pathogenicity. 
Mutations in the genes LRRK2 and SNCA are responsible for the autosomal dominant form 
of the disease through a gain of toxic  function. Mutations in PARKIN, PINK1 and DJ-1 are 
the most common cause of the autosomal recessive form through a loss of protective 
function. 
3. Autosomal dominant PD 
3.1 SNCA (PARK1 and 4, 4p21) 
It was the first gene to be inequivocally associated with familial autosomal dominant PD. It 
encodes for ┙-synuclein, a small protein, which is aboundantly expressed in the brain and 
localized mostly to presynaptic nerve terminals. This protein has a central role in the 
learning process, brain plasticity, vescicular trafficking and dopamine synthesis but many 
aspects of the normal function of alpha-synuclein are still unknown. There is still no good 
explanation for the selectivity of neural damage in PD, which is prominent in dopaminergic 
cells whereas ┙-synuclein is expressed in many areas of the brain. 
Alpha synuclein plays a role in both familial and sporadic form of PD and for this reason 
can be an interesting target for the development of new therapies. 
The protein is linked to the phospolipid membrane strate through the N-terminal edge and 
to a lesser extent it is free in the cytoplasm. It is hypothesized that a possible pathological 
role derives from a conformational change that lead to an imbalance between the protein 
linked to the membrane and that free in the cytoplasm, with a consequent aggregation and 
fibril formation. 
Three missense mutations are causal factor for the familial autosomic dominant form of the 
disease 
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• A53T, identified within an Italian family and three Greek families (Polymeropoulous et 
al., 1997) 
• A30P, identified in a German family (Krüger et al.,1998) 
• E56K, identified within a Spanish family (Zarranz et al., 2004) 
The pathogenic mechanism is supposed to be a conformational change due to the 
amminoacid substitution in the protein chain, which facilitates ┙-synuclein aggregation. 
Clinically, the phenotype is more aggressive with an higher incidence of cognitive 
impairment and autonomic disfunction. SNCA point mutations have so far been found only 
in large, multigenerational PD families, never in sporadic PD. The phenotype of  patients 
with SNCA point mutations is that of L-dopa responsive parkinsonism with a relatively 
early age at onset, rapid progression, and high prevalence of dementia, psychiatric and 
autonomic disturbances, reminiscent of Lewy body dementia. Several family members from 
these kindreds have come to autopsy and they invariably showed cell loss of dopaminergic 
neurons of the substantia nigra, and severe and widespread Lewy pathology, particularly in 
the form of Lewy neuritis. The identification of SNCA point mutations as a cause of PD soon 
led to the discovery that the encoded protein, a-synuclein, is the major fibrillar component 
of Lewy bodies and Lewy neuritis in familial as well as sporadic cases. The currently 
favoured hypothesis settles that the ammoniacid changes within alpha-synuclein lead to an 
increased tendency of the protein to form oligomers and later on fibrillar aggregates, 
representing a ‘toxic gain of function’. However, the precise sequence of events which lead 
from aggregation to cellular dysfunction and cell death is still not obvious. Some studies 
favour the hypothesis that the mature aggregates (Lewy bodies) are not themselves the toxic 
moiety, but rather an attempt to the cell to clear small toxic oligomers. A direct link between 
┙-synuclein and PD was further supported by the discovery that multiplications of the wild-
type sequence of SNCA (duplications and triplications) (Singleton et al., 2003) cause PD with 
or without dementia in some families. This finding was of major mechanicistic importance 
because indicates that an increase in wild-type a-synuclein protein expression appears to be 
toxic to neurons. A dose dependency of this effect is demonstrated by the fact that patients 
with SNCA triplications (4 copies of the gene) have an early age of onset (mean of around 35 
years) and high prevalence of dementia, while patients with SNCA duplications (3 copies) 
have a more typical late-onset PD phenotype.  
The presence of α-synuclein-containing aggregates in the absence of coding SNCA 
mutations in sporadic disease suggest that other ┙-synuclein modifications, such as 
alternative splicing, phosporylation,, alterations in gene expression, or additional interacting 
genes may contribute to sporadic PD. 
Then interaction of ┙-synuclein with proteins aggregating in other neurodegenerative 
diseases is coming increasingly into focus. ‘Cross-seeding’ of ┙-synuclein and tau has been 
hypothesized by a recent study. Interestingly this molecular mechanism may turn out to be 
the biological basis of the recently confirmed and refined association of MAPT haplotypes 
with PD and of an interaction of genetic variants in the SNCA and MAPT genes. 
3.2 LRRK2 (PARK8, 12p21)  
The gene spans a genomic region of 144 Kb, with 51 exons encoding LRRK2 or Dardarin, a 
2527 amino acids protein, with various conserved domains recognized in its primary 
ammino-acid sequence. More than 40 variants have been identified in the gene and at least 
16 of them are recognized as pathogenic ones. Missense mutations in this gene were found 
www.intechopen.com
 Genetics of Parkinson Disease 
 
21 
to cosegregate with the disease in several families and are the most common cause of 
mendelian PD identified so far.  In studies across several populations, 5–15% of autosomal 
dominant PD families carried mutations in LRRK2. One particularly common mutation, a 
base pair change at position 6055,better known as the ‘G2019S-mutation’, is responsible for 
familial PD in up to 7% of cases in different Caucasian populations , but was found, 
somewhat surprisingly, also in 1–2% of sporadic patients. Even higher G2019S prevalence 
rates of up to 40%were found in genetically isolated populations,such as the Ashkenazi 
Jewish and the North-African Arab populations, both in sporadic and familial cases. 
P.G2019S is the most common mutation among Caucasian patients and it is responsible for 
the  0.5-2% of the cases of the sporadic disease and for the 5% of the familial cases. This 
mutation is particularly frequent among the Askenazi Jews and the Arabs from North 
Africa, where it is responsible for 18-30% of the cases. The substitution has been identified 
also in the Iberian Peninsula, where it is involved in the 2.5-65% of the cases of the sporadic 
disease. It seems that the mutation has been originated in North Africa or in the Middle East 
and probably later it has been spread to Europe and Northern America. It has also been 
hypothesized a common founder for the p.G2019S substitution probably dated back to the 
13th Century. The presence of the mutation in the Middle East and in North Africa lead to 
guess that the mutation should be even more older. The Fenices were known to be the 
principal merchants  of the ancient world and probably they were responsible for the 
diffusion of this substitution. 
Due to its relatively high frequency, the p.G2019S mutation offers for the first time the 
possibility of looking at gene–gene interactions. Three Spanish patients simultaneously 
harbouring heterozygous mutations in LRRK2 and in the parkin gene did not present with 
an earlier age at onset or a more severe disease. The G2019S mutation also seems to be fully 
dominant, as homozygous mutation carriers have been identified who also do not differ 
from heterozygotes with respect to disease severity or age of onset. 
Another, even more common LRRK2 variant, G2385R, has been found in the Asian 
population in 6–10% of sporadic PD patients, as opposed to 3–5% of controls. Consequently, 
this variant confers a relative risk of about 2 to 3 of developing PD,suggesting that different 
alterations in one and the same gene may act as a high-penetrance disease-causing mutation 
or as a genetic risk variant in sporadic populations.To date, more than 20 potentially 
pathogenic mutations in LRRK2 have been identified, but in only six of them pathogenicity 
can be considered to be highly likely (R1441C, R1441G,R1441H, Y1699C, G2019S and 
I2020T), because of firm evidence of cosegregation in affected families and functional data 
suggesting an alteration of kinase activity.The most extensive clinicogenetic study so far 
estimated the overall frequency of LRRK2 mutations in the European population to be 
1.5%in sporadic and 4%in familial cases, with a geographic gradient decreasing from 
Mediterranean countries (Spain, Portugal, Italy) to northern countries. The average age of 
onset was 58 years, with a wide range from the mid-20s (rarely) to over 90 years. The clinical 
picture was that of typical asymmetric L-dopa responsive parkinsonism that was 
indistinguishable by any single criterion from PD in individuals without LRRK2 mutations. 
As a group, the disease appeared to be somewhat more benign in patients with mutations in 
LRRK2, with slower progression and a lower frequency of dementia and psychiatric 
complications. 
In contrast to the finding that ┙-synuclein stains Lewy bodies and tau stains neurofibrillary 
tangles and grains, LRRK2 immunocytochemistry has so far failed to highlight any specific, 
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neurodegenerative lesion , and it is unclear how LRRK2 substitutions result in 
neuropathology. LRRK2 mutations may therefore be an upstream event in the cascade 
leading to neurodegeneration with different pathologies. 
LRRK2 is widely expressed in the brain, with highest levels in the striatum and the 
hippocampus but a relatively low abundance in the substantia nigra; it can also be detected 
in other organs, such as the spleen, the lung and the liver. It has been found in the 
cytoplasm as well as associated with membranes. Its function and the mechanism by which 
LRRK2 mutations cause neuronal degeneration are unknown. By sequence homology, 
LRRK2 can be assigned to the group of recently identified ROCO proteins and contains a 
protein kinase domain of the mitogen-activated kinase class, suggesting a role in 
intracellular signalling pathways. Although the natural substrate of LRRK2 is unknown, cell 
culture studies using generic substrates or LRRK2 autophosphorylation paradigms 
suggested that at least some pathogenic mutations seem to be associated with an increase, 
rather than a loss, of kinase activity, and that kinase activity appears to be necessary for 
neurotoxicity in vitro. This discovery raises the interesting possibility that kinase inhibition 
may be a potential therapeutic strategy. An interesting aspect of LRRK2-associated PD is its 
heterogeneous pathology. Post-mortem changes in patients with LRRK2 mutations are those 
of typical Lewy-body PD in most cases, but also include diffuse Lewy-body disease, nigral 
degeneration without distinctive histopathology and, rarely, even aggregates of the 
microtubule-associated protein tau, suggestive of progressive supranuclear palsy or 
frontotemporal dementia. Different pathological findings were even reported in a single 
family with an R1441C mutation. LRRK2 mutations may therefore be an upstream event in 
the cascade leading to neurodegeneration with different pathologies. However, the vast 
majority of patients with a G2019S mutation, in whom pathology has been reported, seem to 
conform to the typical ┙-synuclein Lewy-body type of PD. No direct link between LRRK2 
and ┙-synuclein has so far been demonstrated. ┙-synuclein does not seem to be 
phosphorylated by LRRK2. 
Despite its still poorly understood role in pathogenesis, LRRK2-associated PD is of 
particular interest since it is the first example of a mendelian form of PD that is common 
enough to provide the opportunity to study the development 
of the disease in a sizeable population. Longitudinal studies in presymptomatic mutation 
carriers may reveal premotor changes by clinical, biochemical or imaging methods, 
indicating the very early phases of the neurodegenerative process. It is in this population 
that studies exploring neuroprotective or preventive measures are most promising to yield 
first results 
3.3 UCHL1 (Park 5, 4p14) 
The ubiquitin C-terminal hydrolase-L1 (UCH-L1) was first identified as an abundant (1–2% 
of total brain protein), neuronspecific protein encoded by a 9.5 kb gene product (Day and 
Thompson, 1987; Doran et al., 1983). UCH-L1 is a de-ubiquitinating enzyme that removes 
carboxy-terminal ubiquitin UCH-L1 from substrates but does not break bonds within 
polyubiquitin complexes and results in the recycling of ubiquitin. In addition,UCHL1 
protein is found in several pathological structures including Lewy bodies and some 
Alzheimer's neurofibrillary tangles (Lowe 
et al., 1990). Furthermore, recent studies have identified a single dominant mutant (I93M) in 
two members of a PD-affected family. Inversely, a polymorphism in UCH-L1 (S18Y) has 
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been suggested to reduce the risk of developing sporadic PD. Interestingly, another study 
hypothesizes that UCHL1 may possess two enzymatic activities, hydrolase and ligase 
activity. Overexpression of UCH-L1 variant I93M resulted in an accumulation of ┙-
synuclein. Furthermore, they suggest that this accumulation is due to an ubiquitination of ┙-
synuclein by dimerized UCH-L1. However, the S18Y polymorphic variant of UCH-L1 has 
reduced ligase activity but normal hydrolase activity, 
which may explain the ‘protective' effect of the S18Y polymorphism. With evidence of UCH-
L1 and parkin being involved in certain forms of familial PD, this gives credence to the 
involvement of the UPS in PD. However, it is unclear how UCH-L1 can promote the specific 
neurodegeneration of dopaminergic neurons in familial PD and what role it plays in the 
sporadic form. 
4. Autosomal recessive PD 
The strategies of linkage mapping and positional cloning can also be used to identify loci in 
genes responsible for autosomal-recessive monogenic diseases. This mode of inheritance is 
characterized typically by the occurrence of the disease in siblings while the parents are 
obligatory heterozygous mutation carriers and usually remain healthy. Autosomal-recessive 
PD has clinically been first recognized and characterized in Japan (Ishikawa and Tsuji, 1996). 
Sibling pairs with PD often have much earlier age of onset compared with patients with the 
sporadic disease, which is why the term ‘autosomal-recessive juvenile parkinsonism’(AR-
JP):  has been coined. Since families with a recessive disease are usually much smaller than 
multigenerational dominant pedigrees, linkage analysis is only successful if several families 
mapping to the same locus are included into a study. 
So far, mutations in three genes have been identified in clinically ‘pure’ forms of autosomal 
recessive PD: PARKIN (PRKN, or PARK2), PINK1 (PARK6) and DJ-1(PARK7). PRKN 
encodes for parkin, a cytoplasmatic protein which functions in the cellular 
ubiquitination/protein degradation pathway as an ubiquitin ligase. DJ-1 and PINK1 encode 
for mitochondrial proteins. Genetics mutations in these genes cause PD through the loss of 
the wild-type protein neuroprotective function, leading to oxidative stress, iron 
accumulation and mitochondrial dysfunction. 
They cause PD with earlier onset (<45 years) and slower progression compared to idiopatic 
PD. Three additional recessive genes have been added to the list more recently-ATP13A2, 
PLA2G6 and FBXO7- which all also cause, when mutated, an early-onset disease with 
parkinsonism, but also with additional features such as dystonia, which often is seen as the 
first symptom, dementia, oculomotor disturbances and spasticity.  
4.1 PARKIN (PARK2, 6q25.2-q27) 
Juvenile cases of parkinsonism in siblings were first recognized in Japan. The first genetic 
locus for autosomal- recessive juvenile parkinsonism (AR-JP), as this form of PD was called, 
was mapped to chromosome 6. 
Mutations were then identified in a large gene in that region that was called parkin. 
Clinically, these patients suffer from L-dopa-responsive parkinsonism and often develop 
early and severe L-dopa-induced motor fluctuations and dyskinesias. Some show diurnal 
fluctuations, with symptoms becoming worse later in the day. Dystonia at onset of the 
disease is common. Parkin mutations turned out to be a common cause of parkinsonism 
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with early onset, particularly in individuals with evidence of recessive inheritance. Nearly 
50% of families from a population of sibling pairs with PD had parkin mutations. Also, parkin 
mutations are responsible for the majority of sporadic cases with very early onset (before 
age 20), and are still common (25%) when onset is between 20 and 35. Prevalence is almost 
certainly well below 5% in those with onset later than 45. Several studies have described the 
clinical spectrum of parkin-associated parkinsonism. Mean age at onset in a European 
population was 32 years; progression of the disease was usually relatively slow, but L-dopa-
associated fluctuations and dyskinesias occurred frequently. Dystonia (usually in a lower 
extremity) at disease onset was found in about 40% of patients, and brisk reflexes of the 
lower limbs were present in 44%. Psychiatric abnormalities have been recognized in PD 
patients with parkin mutations but there are no systematic studies to determine whether this 
is a characteristic feature associated with parkin-mutations. Phenotype– genotype studies 
implicate that the type of mutation may influence the clinical phenotype to a certain degree: 
patients with at least one missense mutation showed a faster progression of the disease with 
a higher UPDRS (United Parkinson’s Disease Rating Scale) motor score than carriers of 
truncating mutations. Missense mutations in functional domains of the parkin gene resulted 
in earlier onset. It is still controversial whether heterozygous mutations in the parkin gene 
can cause parkinsonism or can confer an increased susceptibility for typical late-onset PD. 
There is evidence from imaging studies that heterozygous carriers of parkin mutations have 
reduced uptake of fluorodopa in the basal ganglia. Furthermore, families with heterozygous 
mutation carriers manifesting symptoms of PD have been described. On the other hand, the 
frequency of heterozygous mutations in the parkin gene was found to be similar in elderly 
healthy individuals, as compared to a cohort with late-onset typical PD and in a large family 
reported recently, 12 heterozygous carriers of a particular parkin mutation (ex3delta40) were 
asymptomatic. Also, in a group of families with PD showing anticipation (late-onset PD in 
the parent generation and early-onset PD in the offspring) genotyping results did not 
support the explanation that the presence of single or compound heterozygous parkin-
mutations contribute to this phenomenon. Therefore, at present the data are still insufficient 
to confidently judge the role of single heterozygous parkin mutations in the development of 
PD. Knowledge on the neuropathology of molecularly confirmed cases of AR-JP is still 
based on only a few cases. Severe and rather selective degeneration of neurons in the 
substantia nigra and the locus coeruleus, usually with absence of Lewy bodies, has been 
described. 
As mutations in parkin cause parkinsonism, in all likelihood by a loss-of-function mechanism, 
the study of the normal function of parkin provides insight into the molecular pathogenesis of 
the disorder. Several groups have now shown that parkin, a protein found in the cytosol but 
also associated with membranes, functions in the cellular ubiquitination/protein degradation 
pathway as a ubiquitin ligase. It has been hypothesized that the loss of parkin function may 
lead to the accumulation of a nonubiquitinated substrate that is deleterious to the 
dopaminergic cell but, due to its nonubiquitinated nature, does not accumulate in typical 
Lewy bodies. Several proteins have been shown to interact with parkin. However, the putative 
toxic protein, which has been hypothesized to accumulate due to the lack of parkin in patients 
(or in knock-out animals) has not yet been identified. However, novel functions of parkin are 
being identified, and it is possible that they may be of equal or even greater relevance to the 
pathogenesis of PD. For example, it has been shown that parkin does not only mediate the 
well-studied ubiquitinylation via lysin48 (K48), which directs ubiquitinylated proteins for 
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proteasomal degradation, but also via lysin63 (K63), which may play a role intracellular 
signaling processes and also in Lewy body formation. A recent study revealed a decreased 
abundance of a number of proteins involved in mitochondrial function or oxidative stress, 
accompanied by a reduction in respiratory capacity of striatal mitochondria, a decreased 
serum antioxidant capacity and increased protein and lipid peroxidation These novel findings 
indicate that proteasomal dysfunction, although supported by several lines of evidence, might 
not be the sole mechanism contributing to neurodegeneration in parkin-related disease. 
Whatever the mechanism, increasing evidence suggests an important role of parkin for 
dopamine neuron survival. Overexpression of wildtype rat parkin could protect against the 
toxicity of mutated human A30P ┙-SYN in a rat lentiviral model of PD. The parkin mediated 
neuroprotection was associated with an increase in hyperphosphorylated ┙-SYN inclusions, 
suggesting a key role for parkin in the genesis of Lewy bodies. Recently, two biochemical 
modifications of Parkin (S-nitrosylation and dopamine quinine-adduct formation) were 
identified in cellular studies and human brain specimens. These data indicated that reduced 
E3-ligase activity of the wild-type Parkin protein (rather than an autosomal recessive mutation 
in the two Parkin alleles) could also occur as a result of the principal pathogenetic process that 
is responsible for the development of sporadic PD. 
4.2 PINK1 (PARK6, chr.1p35-1p36) 
The new locus was identified in a large Italian family and it causes familial recessive PD in 
1-9% of the cases. The phenotype was similar to that seen with PRKN mutations and 
characterised by early-onset parkinsonism (range 32 to 48 years), with slow progression and 
sustained response to L-dopa. In this and two other consanguineous PARK6- linked 
families, two different mutations in the gene PINK1 (encoding PTEN-induced putative 
kinase 1) were identified. Several studies confirmed the presence of PINK1 mutations in 
patients with early-onset PD. Most mutations were missense mutations in conserved 
regions, but whole-gene deletions have also been described. Almost all described patients 
with PINK1 mutations have slow disease progression and a good response to L-dopa. As in 
PRKN related disease, except for the earlier average age of onset, no single feature can 
separate PINK1-related disease from idiopathic PD. There are some indications that PINK1- 
mutated patients have a higher prevalence of psychiatric disturbances, particularly anxiety 
and depression, which is only relatively rarely observed in PRKN-related cases . Wild-type 
PINK1 is thought to function as a protein kinase with possible activity inside the 
mitochondria, thereby strengthening the hypothesized link between mitochondrial 
dysfunction and oxidative stress in PD pathogenesis. 
4.3 DJ-1 (PARK7, chr.1p36)  
The third locus for AR-JP, PARK7, was mapped also to chromosome 1p36, in a Dutch 
family, and the gene was identified as the oncogene DJ-1. Again, the phenotype closely 
resembles that found in patients with PRKN and PINK1 mutations, but this statement is 
based on a small number of identified patients.Mutations in the gene are responsible for 1-
2% of the AR-JP. However, one recessive family, which carries two homozygous mutations 
in the DJ-1 gene, has been described with early-onset parkinsonism, dementia and 
amyotrophic lateral sclerosis, suggesting that the clinical phenotype associated with 
mutations in this gene, although rare, may be rather wide.  
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There are now eight recessive loci, which can lead to EOPD syndromes. These are the 
classical recessive loci, PRKN (PARK2), PINK1 (PARK6), DJ-1 (PARK7). Loss of function 
mutations at PRKN, PINK1, and DJ-1 nearly always give rise to a pure parkinsonian 
phenotype which has an early onset, a benign course, sleep benefit and a good and 
prolonged response to L-dopa. The lifespan of mutation carriers is only marginally reduced 
and there have been no reports of brain iron accumulation. All three proteins have functions 
related to mitochondrial biology and PRKN mutations are usually not associated with Lewy 
bodies. More recently, five other genes, ATP13A2 (PARK9), PLA2G6 (PARK14), FBX07 
(PARK15) and SPG11 and the PANK2, have been identified that cause early-onset forms of 
parkinsonism associated with a variety of other signs and symptoms, including, in variable 
combinations, dystonia, ataxia, spasticity and dementia. 
4.4 ATP13A2 (PARK9, 1p36) 
It was the first of these genes to be characterized, encoding a predominantly neuronal P-
type ATPase, in a recessively inherited early-onset parkinsonian syndrome described as 
‘Kufor- Rakeb syndrome’ . Patients with this disease have rapidly progressive 
parkinsonism, spasticity, vertical upgaze palsy and dementia. The substrate and function of 
the protein is unknown. The wild-type protein was found to be located in the lysosome of 
transiently transfected cells, while the unstable truncated mutant proteins were retained in 
the endoplasmic reticulum and degraded by the proteasome. It can be speculated that either 
overload of the proteasomal protein degradation machinery or lysosomal dysfunction due 
to the absence of sufficient levels of ATP13A2 protein might lead to neurodegeneration. In 
fact, there is increasing evidence for an important role of the lysosome in the aetiology of 
PD: ┙-synuclein is degraded by chaperone mediated autophagy, and mutations in the gene 
encoding lysosomal glucocerebrosidase are an important cause of PD. Nevertheless, a direct 
involvement of the lysosome in the neurodegenerative process in Kufor-Rakeb syndrome 
and its potential bearing for PD remains speculative at this time  
4.5 PLA2G6 (PARK14, 22q13.1) 
Another interesting addition to the recessive genes causing parkinsonian syndromes that 
may give important insight into underlying pathogenetic processes is the gene for 
phospholipase A2 group VI (PLA2G6). Mutations in this gene have been identified in two 
recessive childhood-onset disorders: infantile neuroaxonal dystrophy (INAD) and 
neurodegeneration with brain iron accumulation (NBIA). There is brain iron accumulation 
in some patients with INAD, so when gene mapping identified a common locus in families 
with these disorders on chromosome 22, it was reasonable to suspect that the disorders may 
be allelic. In fact, a large number of mutations were identified, including missense changes, 
small deletions with and without frameshift, nonsense mutations and large deletions. As 
patients with two null mutations tended to have the most severe phenotype, a loss of 
function mechanism can be assumed. Interestingly, in addition to axonal swellings 
throughout the cortex, striatum, cerebellum, brainstem and spinal cord, the pathological 
picture also includes a-synuclein positive Lewy bodies, and thus these disorders share this 
important pathological feature with PD. Lewy bodies are also found in another form of 
neurodegeneration with brain iron accumulation (NBIA type 1; formerly called 
Hallervorden–Spatz disease), caused by mutations in the gene for pantothenate kinase 2 
(PANK2). Therefore, there seems to be an interesting but still little understood link between 
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iron accumulation (which is also found in PD proper), a-synuclein aggregation, and 
neurodegeneration with parkinsonian symptoms.While the ‘classic’ phenotype of NBIA 
types 1 and 2 is that of a young-onset progressive extrapyramidal-pyramidal syndrome with 
visual disturbance through optic atrophy or pigmentary retinopathy, mutations in both 
genes can be associated with a parkinsonian syndrome of later onset. Recently, PLA2G6 
mutations have been identified in patients with adult-onset L-dopa-responsive dystonia–
parkinsonism, pyramidal signs and cognitive/psychiatric features, and cerebral and 
cerebellar atrophy on magnetic resonance imaging but lack of iron in the basal ganglia. 
4.6 FBXO7 (PARK15, 22q12-q13) 
Finally, mutations in a novel and still poorly characterised gene, FBXO7, have been found in 
members of two families with early-onset, progressive parkinsonism and pyramidal tract 
signs, a phenotype that had been described clinically as the pallidopyramidal syndrome. 
Loss of function mutations in FBX07 appear to give a phenotype which resembles PRKN 
mutation associated phenotype  but the disease is generally less benign and has a reduced 
life expectancy, pyramidal signs and late cognitive problems. This overlap of phenotypes 
related to FBX07 and PRKN mutations is consistent with the related functions of these two 
genes and their likely common disease pathway. Like PRKN, F-box proteins, such as 
FBXO7, are components of the modular E3 ubiquitin protein ligases. The genetic 
heterogeneity was surprising given their initially common clinical features 
5. Role of heterozygous mutations in ‘recessive’ genes 
A considerable percentage of patients with PD was shown to carry a single heterozygous 
mutation in the Parkin, DJ1 or PINK1 genes, raising the intriguing question of whether the 
much more frequent heterozygous mutations in ‘recessive’ genes might act as susceptibility 
factors for PD. Several ways lead to explore the potential role of these mutations. First, the 
frequency of single heterozygous mutations in ethnically matched PD cases and controls 
could be compared. According to recent reports, heterozygosity for Parkin mutations was 
similar between patients and controls, whereas heterozygous PINK1 mutations were rarer in 
controls. Lincoln et al. indicated that there was no elevation in PD risk for people who carry 
a single mutant Parkin allele. In most studies, however, healthy controls are not subjected to 
detailed neurological and neuroimaging examinations, leaving open the possibility that 
mild clinical (or preclinical) changes could have been present but were not screened for. As 
recently shown for Parkin and PINK1 families, subtle, but unequivocal, clinical signs of 
possible or probable PD can be found on careful motor examination in a considerable 
number of the heterozygous mutation carriers who consider themselves asymptomatic. 
Furthermore, it could be argued that at least some of the controls had not yet reached the 
age of their disease onset. Second, the heterozygous offspring of homozygous or compound 
heterozygous mutation carriers could be examined in a prospective manner, an approach 
that is currently being used in several cohorts. The probability that a second mutation might 
have been overlooked in these carriers is much lower than the probability of a mutation 
being missed in sporadic cases of PD. Last, further functional studies of the affected allele 
carriers would be highly valuable. Haploinsufficiency, leading to a functional loss of 
heterozygosity or a dominant-negative effect of some mutant alleles, could explain why a 
second mutation cannot (and need not) be found for some mutations in the above-
www.intechopen.com
  
Etiology and Pathophysiology of Parkinson's Disease 
 
28
mentioned recessive genes. Although the role of heterozygous mutations in the 
development of clinical signs currently remains a matter for debate, there is growing 
evidence that they are associated with pre clinical changes. PET studies have revealed 
reduced [18F]fluoro-dopa uptake by nerve terminals in the striatum of heterozygotes; there 
are also structural neuroimaging changes that indicate an increased deposition of metals in 
the substantia nigra, and there is reorganization of striatocortical motor loops with 
detectable changes in connectivity patterns.These collective data have important 
implications. Some carriers of heterozygous mutations might be in the preclinical period of 
PD, thereby affording unique opportunities to examine the relative risk associated with the 
affected allele and to study the natural history of the disease. This group also represents an 
ideal study population to be used not only to investigate compensatory mechanisms, 
facilitating the development of a sensitive surrogate marker, but also to detect the earliest 
PD-specific changes, allowing the development of urgently needed clinical biomarkers. 
Finally, these individuals could provide a small, but important, target population in which 
to evaluate the ‘proof of principle’ of a therapeutic intervention in future neuroprotection 
trials. 
6. Sporadic PD 
Sporadic PD is multifactorial, complex and polygenic, generally determined by several 
common non-coding genetic variants, each of them play a role as a very modest risk factor 
singularly but with an important cumulative effect taken all together,  interacting with 
environmental factors, other genes or functional variants, controlling the expression, splicing, 
phosphorylation, influencing the age at onset, severity and progression of the syndrome. 
Association studies have been widely used in an attempt to identify common genetic 
variations that carry a mild to moderately increased risk to develop a disease. Over the 
years, literally hundreds of studies have been published, but unfortunately, only very few of 
them have produced robust and reproducible results. Several are the reasons which can 
justify the failure of this approach: most studies were greatly underpowered in relation to 
the small increases in the relative risk that today are known to be conferred by common 
genetic variants (usually the odds ratios are in the range of 1.2–2, with some exceptions, for 
example apolipoprotein E for AD). Then the choice of candidate genes was often based on 
rather arbitrary rationales with very weak experimental or epidemiologic evidence. As the 
gene-mapping studies in monogenic diseases have shown, newly identified genes most 
often could not have been predicted based on the current knowledge of pathogenesis. 
Furthermore in most studies only arbitrarily chosen individual genetic variants were 
investigated, thus it was a priori unlikely that the causative variant or a variant in high 
linkage disequilibrium, tagging the risk-conferring variant, would be among those studied. 
Finally, it is not easy to match patient and control cohorts with respect to their genetic 
background. Often, due to different recruiting strategies, these cohorts differ in their genetic 
composition (a problem called undetected population stratification, which today can be 
easily resolved in GWAS, see below). Due to different allele frequencies in different 
populations, spurious associations can be detected. 
In the idiopatic cases an attempt is made to evaluate the PD population as a whole, using 
association studies and non parametric linkage methodology and trying to define risk alleles 
that contribute to the sporadic form of the disease. 
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Common genetic variants in SNCA can increase the susceptibility for idiopatic PD,  while 
the LRRK2 p.G2019S mutation can cause sporadic PD. Recently GWAS discovered new 
genes associated with PD: GBA, MAPT, GAK, BST1, HLA, LONGO1and LONGO2, PARK16, 
SYNPHILIN. 
6.1 SNCA (PARK1-4, 4q21) 
Previous studies have found associations between Parkinson’s disease and polymorphisms 
located within both the ┙-synuclein gene promoter and other gene regions. Particularly 
interesting is a complex polymorphic dinucleotide repeat polymorphism (NACP-REP1), 
located 10 kb upstream of the transcriptional start site of SNCA. In this case the number of 
dinucleotide repeats are directly linked to an higher risk to develop PD. Indeed the 263 
haplotype is associated to the disease while the 259 one has a protective effect. 
The SNCA gene consists in two haplotype blocks (genetic regions usually inherited as a 
single block, with a high degree of Linkage disequilibrium). The first block ranges from the 
promoter region to intron 4 while the second block includes exons 5 and 6 and the 3’-
untraslated region. The second block gives the strongest association signal with PD. 
Becasuse the SNP variability is noncoding and not within a region of species-conserved 
sequence identity or a miRNA binding site, the biologic mechanism remain unclear. 
Alternative splicing, phosporilation, expression modification or even linkage disequilibrium 
with another functional variant within the gene have been hypothesized as possible 
mechanisms. Gene expression may also be influenced by epigenetic interactions, including 
methylation, recently implicated in the downregulation of SNCA gene expression, which 
may warrant further investigation.  
6.2 LRRK2 (PARK8,12q12) 
Even if mutation in LRRK2 are the most common cause of familial autosomal dominant PD,  
the p.G2019S substitution is of special significance as it is frequently identified not only in 
autosomal dominant, but also sporadic PD. Thus, being the most common cause of PD. The 
mutation is particularly frequent in PD patients residing in, or having genealogical ties to 
North Africa or the Middle East. This phenomenon can be explained by the fact that most 
LRRK2 p.G2019S substitution carriers originate from a common founder. 
6.2.1 The LRRK2 c.6055G>A (p.G2019S) mutation 
P.G2019S is located in the mitogen-activated protein kinase (MAP) domain of the LRRK2 
protein. The identification of p.G2019S substitutions as the most common cause of both 
familial and sporadic PD has been a major breakthrough. The frequency of p.G2019S 
substitutions differ remarkably throughout the world. This is due to a common founder for 
most p.G2019S carriers, originating from the Middle East or North Africa. Two large studies 
on Lrrk2 p.G2019S parkinsonism conclude that the phenotype of Lrrk2 p.G2019S can not be 
distinguished from idiopathic PD. There are some indications of a more benign course of 
p.G2019S parkinsonism compared to idiopathic PD with a slower disease progression and 
less cognitive impairment. However, methodological issues may have contributed to these 
observations. The penetrance of Lrrk2 p.G2019S has been much debated over the last years. 
Hulihan et al. investigated sporadic PD in Tunisia and found a lifetime penetrance of 45% 
(95% CI: 20–100%) for p.G2019S substitution carriers. Healy et al. additionally included 
hereditary patients and estimated that 74% had PD by age 79 years. Interestingly, 
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homozygous p.G2019S carriers do not have more severe disease than heterozygous carriers, 
this lack of gene-dose effect is consistent with the hypothesis that the p.G2019S substitution 
increases kinase activity. The pathology of p.G2019S parkinsonism is consistent with LBD in 
most, but not all cases. 
6.3 GBA (1q21) 
GBA is responsible to cause Gaucher Disease, GD, when the mutation is present in 
homozigosity. Patients with GD and relatives have an increased susceptibility for PD (2-3 
fold), susceptibility which can increase among different populations like Ashkenazi Jews (5-
6 fold), when the mutation in the gene is present in heterozigosity. GBA encodes a lysosomal 
enzyme that cleaves glucocerebroside. As ┙-synuclein is in part degraded by chaperone-
mediated lysosomal pathway, it is conceivable that GBA mutations may increase the risk for 
PD by altering cellular ┙-synuclein homeostasis. It is supposed that the pathologic effect is 
due to the lack of the physiologic function or gain of a toxic one. Neuropathologically, Lewy 
bodies are present in the hippocampal region, corresponding to Braak stages 5 and 6, 
indicating that the dementia can be very similar to Lewy bodies dementia. Phenotipically 
GBA mutations carriers present the clinical features of sporadic PD with an higher and more 
severe incidence of dementia, olphactory disfunction, bradikinesia and a lower frequency of 
rigidity. 
6.4 MAPT (17q21.1) 
MAPT, encodes for the microtubule associated protein tau. Risk alleles of the associated 
SNPs are in LD with the H1 haplotype. An association between MAPT locus and PD could 
seem surprising, given the classic separation of synucleinopathies and tauopathies but the 
role of MAPT in neurodegenerative diseases is well established and this association is 
biologically plausible, despite the lack of neuropathology in PD. The combination of risk 
variants in MAPT and SNCA doubles the risk of developing PD, supporting the idea that 
related pathways contribute to neurodegenerative diseases. Finally, although we do not 
understand the relationship between the MAPT locus and Parkinson disease, it is worth 
remembering that while LRRK2 mutations usually give rise to a-synuclein pathology, they 
sometimes give rise to tangle pathology (Zimprich et al., 2004) and that, while MAPT 
mutations usually give rise to tangle pathology, they sometimes give rise to Lewy body 
pathology. 
An association to MAPT is absent in the Asian population. 
6.5 GAK (4p16) 
GAK (cyclin G associated kinase, a cell cycle regulator) is a serine thereonine kinase. It is a 
particularly promising candidate because it is one of 137 genes shown to be differentially 
espressed in PD, with an 1.56 fold change in expression in the substantia nigra pars 
compacta of PD patients compared to controls. Protective role postulated: decreased in 
expression or depletion enhance alpha-synuclein toxicity. 
6.6 BST1 (4p15) 
BST1(bone marrow stromal cell antigen) catalyses the formation of cyclic ADP-ribose 
(cADPR). cADPR mobilizes calcium (Ca2+) from ryanodine sensitive intracellular Ca2+, 
stored in the endoplasmic reticulum. Distruption of the Ca2+ homeostasis has recently been 
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proposed of a possible cause of selective vulnerability of dopaminergic neurons in PD. 
Associated SNPs in the BST1 region may modify ADP-ribosylcyclase activity, thus leading 
to Ca2+ dyshomeostasis in dopaminergic neurons. 
6.7 HLA (HLA-DRA; HLA-DQ;HLA-DR (6p21.3) 
The HLA variant that displayed the strongest statistical association with Parkinson’s disease, 
rs3129882, is a noncoding polymorphism in intron 1 of HLA-DRA. The protein chains encoded 
by the closely linked HLA-DRA and HLA-DRB form the class II HLA-DR antigens that are 
expressed by antigen-presenting cells, including microglia in the brain, and which interact 
with T-cell receptors. HLA-DRB chains are highly variable and have been associated with 
numerous disorders, including multiple sclerosis, which, like Parkinson’s disease, is a 
progressive neurodegenerative disorder. HLA-DRA, on the other hand, is practically 
monomorphic and therefore has not been investigated for disease association. The 
conventional explanation for this finding is that PD is associated with a classical polymorphic 
HLA antigen and that rs3129882 is a proxy for this antigen. Alternatively, the association of 
Parkinson’s disease with an intronic DRA variant may reflect involvement of regulatory 
elements, which would be in line with Parkinson’s disease–specific overexpression of DR 
antigens in substantia nigra. The evidence for genetic association of PD with HLA region, 
particularly when obtained from a hypothesis free-GWAS, where the entire genome is scanned 
without pre-existing bias towards any particular genes, lends strong and independent support 
to the involvement of neuroinflammation and humoral immunity in Parkinson’s disease 
pathogenesis. Studies have shown elevated DR expression in the brain and cerebrospinal fluid 
of individual with PD. The sustained presence of reactive DR positive microglia has been 
observed in the substantia nigra of individuals with PD, as well as animals and humans 
affected with 1-methyl-4-phenyl-1,2,3,6,-tetrahydropiridine-induced (MPTP)  parkinsonism. It 
is postulated that chronic immune activation and neuroinflammation occurs in response to an 
initial trigger, possibly related to alpha-synuclein accumulation, and produces neurotoxins 
and oxidative damage that could kill neurons. From a therapeutic perspective, vaccination 
aimed neutralizing neuroimmune dysfunction was recently shown to attenuate 
neurodegeneration in a Parkinson’s disease model: further, NSAID use is associated with 
reduced reduced risk of developing PD in humans. The newly discovered association of PD 
with HLA region highlights the involvement of an important biological pathway in the 
etiology of the disease and point to a potential drug target that will stimulate research toward 
new therapies.  
6.8 LINGO1 and LINGO2 (15q24.3)(9p21.2) 
A significant overlap between the diagnoses of PD and essential tremor (ET) is frequently 
observed. In retrospective analyses, 6-20% of ET patients have been described to exhibit 
signs of Parkinsonism. A recent prospective study demonstrated that patients with ET have 
a four-fold elevated risk to develop PD over an observational period of 3.3 years. 
Conversely, a diagnosis of ET was proposed to be 5 to 10 times more likely in subjects with 
PD than in controls. Furthermore it has been demonstrated that the risk of ET in first-degree 
relatives of patients with PD is significantly elevated. A neuropatholgical study 
demonstrated the occurrence of Lewy bodies in the brainstem in an older subset of ET 
patients. Genetic variation in the leucine-rich repeat and Ig domain containing Nogo 
receptor interacting protein1, (LINGO1) and its paralog (LINGO2) was recently associated 
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with an increased risk of developing essential tremor (ET) and  Parkinson’s disease (PD). 
LINGO1 plays a role in early brain development and oligodendrocyte differentiation. 
Because of its presumed role in neural survival and myelination, LINGO1 has been targeted 
in vivo and in vitro in model of spinal cord injury, autoimmune encephalitis and PD. 
6.9 PARK16(1q32) 
The PARK16 region contains five functionally interesting candidate genes for PD etiology. 
SLC41A1 is a magnesium (Mg2+) transporter. It is of interest that Mg2+ deficiency is 
thought to be an environmental risk factor for the amyotrophic lateral sclerosis (ALS)-
parkinsonism/dementia complex. Furthermore, RAB7L1 is a small GTP-binding protein that 
plays an important role in regulation of exo-and endocytotic pathways, and NUCKS1 is a 
nuclear protein containing several consensus phosphorylation sites for casein kinase II and 
cyclin-dependent kinases of unknown function.  
Although pathogenic mutations and risk alleles within the PARK16 locus seem to be rare in 
European ancestry populations, further molecular analyses within different populations are 
required to examine its biochemical role in PD. 
6.10 Synphilin 
The presynaptic protein synphilin 1 and its isoform 1A have been associated with PD. 
Synphilin is an interactor of ┙-synuclein and is modulated by parkin.  Synphilin is widely 
expressed with highest levels in brain, heart and placenta.  
6.11 Omi/HtrA2 (PARK 13, 2p12) 
In vitro and in vivo studies strongly implicate loss of Omi/HtrA2 protein in disrupted 
mitochondrial homeostasis and subsequent cell death. Moreover, recent pathoanatomical 
studies indicate that Omi/HtrA2 represents a consistent pathological marker  for  
neurodegeneration in different ┙-synucleinopathies (Kawamoto et al.,2008). Loss of 
Omi/HtrA2 function may contribute to a broader spectrum of neurodegeneration, as 
decreased levels of Omi/HtrA2 were demonstrated in brains of Huntington’s disease patients. 
Therefore, while some genetic association studies provide no consistent support for an 
association of  Omi/HtrA2 and PD, functional studies suggest that further study of this gene in 
the context of neurodegenerative disorders is justified. We cannot exclude the possibility that 
other neurodegenerative diseases besides PD may be influenced by Omi/HtrA2 variations.  
Recent discoveries from meta-analysis study of previous GWAS, identified 11 loci that 
surpassed the threshold for genome-wide significance (p<5x10(-8)). Six were already known 
loci (MAPT, SNCA, HLA-DRB5, BST1, GAK and LRRK2) and 5 were newly identified loci 
(ACMSD, STK39, MCCC1/LAMP3, SYT11 and CCDC62/HIP1R) (International Parkinson’s 
Disease Genomic Consortium, 2011) 
ACMSD is involved in picolinic and quinolinic acid homoeostasis and is a possible 
therapeutic target for several disorders that affect the CNS. The locus identified near STK39 
has been associated with autism and infl ammatory status, although there have been no 
reports of this locus contributing to neurodegenerative phenotypes. The LAMP3 locus might 
modulate neurosecretory function in PC12 cell lines. 
HLA-DRB5 is involved in multiple sclerosis, immunocompetence, and histocompatibility. 
The association with Parkinson’s disease at HLA-DRB5 supports the theory that 
inflammatory factors are associated with the pathogenesis of PD.  
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7. Pathogenic pathways 
Familial and sporadic PD present similar clinical features, which reinforce the hypothesis 
that common pathways might be at the basis of a so analogous phenotype. Generally 
dystonia appears as  the first symptom in the familial cases, while gait impairment and 
postural instability are one of the first manifestation for the sporadic ones. Evidence is 
emerging that some of the pathways covered in the rare monogenic forms of PD: 
dysfunction or impairment of the ubiquitin-proteosome system and/or mytochondria, may 
play a direct role in the etiology of the common sporadic disorder and genetic variation 
contribute to the risk of developing PD. 
So far, the proteins that have been linked to parkinsonism by genetic studies have roles 
in: 
• mitochondrial function (┙-synuclein, PARKIN, PINK1, DJ-1, FBXO7, Omi/HtrA2, 
POLG1) 
• lysosome (GBA, ATP13A2) 
• the ubiquitin–proteosome system (PARKIN and UCHL1) 
• vescicle dynamics (┙-synuclein), 
• MAPKKK signaling (LRRK2), 
• oxidative stress 
• microtubule stability (MAPT) 
• embryonic development (┙-synuclein, PARKIN, UCHL1, LRRK2, Omi/HtrA2, NURR1, 
PITX3) 
These disparate functions might overlap as they all lead to the age-associated dysfunction 
and death of dopaminergic neurons that characterize PD. However, the relationships 
between these functions are not direct and the connections between them are not 
immediately evident.  
7.1 Mitochondrial dysfunction (α-synuclein, PARKIN, PINK1, DJ-1, FBXO7, POLG1, 
Omi/HtrA2)  
The pathway that has come most clearly out of the analysis of the Mendelian genes is a 
mitochondrial damage repair pathway. ┙-synuclein has long been known to modulate 
mitochondrial function, but the mechanism remains unknown. A possible role in 
mitochondrial signaling has been hypothesized. Parkin enhances transcription and 
replication of mitochondrial DNA in proliferating cells. Furthermore, Parkin, an E3 
ubiquitin ligase, and PINK1, a mitochondrial kinase, are involved in the elimination of 
damaged mitochondria. DJ-1, and possibly FBX07, another ubiquitin ligase, are also likely to 
play a role in the mitochondrial pathway. DJ-1 can protect the cell against oxidative stress 
and can also translocate to the mitochondria. (Cookson 2010). The similar phenotype can 
confirm a common role of these genes in the mitochondrial pathway (Paisan-Ruiz et al., 
2010; Valente et al., 2004;Yamamura 2010). 
POLG1 is a mitochondrial DNA polymerase (Polymerase gamma 1) of the inner 
membrane that synthesizes, replicates and repairs mitochondrial DNA. Several mutations 
within POLG1 have been associated with parkinsonism in addition to other clinical 
phenotypes. 
HtrA2 also known as Omi (HtrA2/Omi) is serine protease localized to the inner membrane 
space of mitochondria. A variation within Omi (G399S) was found in four patients with late-
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onset PD and a polymorphism (A141S) has been suggested to be a risk factor in Germans. 
Furthermore, a possible implication has been demonstrated by animal models: knocking out 
Omi in mice leads to neurodegeneration with features of motor neuron dysfunction, ataxia 
and parkinsonism with striatal damage. 
In addition MPTP can damage in a selective way dopamine neurons and mitochondria 
causing parkinsonism. (Langston 1989). 
7.2 Lysosome pathway (GBA, ATP13A2) 
A second pathway that is likely to be involved in Parkinson disease clearly involves the 
lysosomes. Proteins with short half-lives are mostly degraded by the proteasome 
whereas most cytosolic proteins with half lives longer than 10 hours are degraded by the 
autophagy- lysosome pathway. Glucosecerebrosidase, GBA, and ATP13A2 are lysosomal 
enzymes.  A role of GBA protein in PD is suggested by the clinical observation of 
association of PD with Gaucher’s disease. Patients with this well characterized recessive 
neurometabolic disease, caused by mutation in the glucocerebrosidase gene (GBA) have a 
high prevalence of PD. Screening of PD patients for GBA mutations found a higher 
number of heterozygous mutations carriers as compared to healthy controls. GBA 
encodes a lysosomal enzyme that cleaves glucocerebroside. As ┙-synuclein is in part 
degraded by chaperone-mediated lysosomal pathway, it is possible that GBA mutations 
may increase the risk for PD by altering cellular ┙ -synuclein homeostasis. Within the 
chaperone-mediated lysosomal uptake pathway ┙-synuclein binds lysosomal membrane 
receptors before being selectively translocated into the lysosome. Mutant ┙-synuclein 
also binds to receptors, but instead of being translocated sufficiently blocks not only its 
own uptake but also uptake of other substrates. Mutations in ATP13A2, a lysosomal 
ATPase, cause autosomal-recessive early onset PD further linking lysosomes to 
neurodegeneration 
7.3 Ubiquitin proteosome pathway (PARKIN, UCHL1) 
The ubiquitin proteasome pathway has been strongly implicated in PD pathogenesis. Parkin 
functions as an E3 ubiquitin ligase. Some disease causing mutations within parkin impair its 
ligase activity leading to intracellular accumulation of parkin substrates. Accumulation of 
potentially toxic proteins might be especially detrimental for vulnerable neurons like 
dopaminergic neurons. Furthermore a missense mutation has been described in UCHL1, a 
deubiquitylating enzyme. The I93M substitution decreases UCHL1 enzymatic activity in 
vitro. Deubiquitylation is an important process to recycle ubiquitin monomers from proteins 
that have been targeted to the proteasome. In addition overexpressed wildtype or mutant ┙-
synuclein has been shown to inhibit proteasome function in vitro and in vivo, even if not 
directly involved in the proteosomal pathway. 
7.4 Embryonic development (α-synuclein, PARKIN, UCHL1, LRRK2, Omi/HtrA2, 
NURR1, PITX3) 
┙-synuclein is important not only in brain but also in peripheral tissues during normal 
human prenatal development. From 15 to 23 gestational weeks ┙-synuclein is expressed in 
almost all fetal human organs while in adult human tissues an high alpha-synuclein 
expression can be observed only in the brain. 
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Parkin expression is correlated with cell maturation and implicates a physiological role of 
parkin in various types of neurons. UCHL1 is highly expressed in cultured NPCs (neural 
progenitor cells) as well as in embryonic brain in general. UCHL1 has been shown to be 
involved in regulating morphology of NPCs and in mediating neurogenesis. Involvement of 
LRRK2 in neurite outgrowth might explain high expression levels in the first two or three 
weeks after birth. Omi/HtrA2 is found in various fetal tissues. Loss of Omi/HtrA2 (mouse 
mutant mnd2, motor neuron degeneration2) leads to muscle wasting, neurodegeneration, 
involution of the spleen and thymus, and death by 40 days of age. Since dopaminergic 
neurons have long been central to PD research and genes involved in development of these 
cells deserve special attention. Dominant mutations in Nurr1 have been reported in families 
with late onset PD. Nurr1, a member of the nuclear receptor superfamily of transcription 
factors  is critically involved in the development of ventral midbrain dopaminergic neurons. 
Mutations within Nurr1 have not been found again, association studies turned out to be 
negative in most studies. In addition (mice deficient for PITX3), a homeobox transcription 
factor, which is expressed from E11 to adulthood, fail to develop dopaminergic neurons of 
the substantia nigra . Taken together several PD associated genes are expressed during 
development. The potential involvement of these genes in early stages of the disease 
remains to be determined. Additionally PD is by no means restricted to dopaminergic 
neurons. It will be of great interest to identify genes with involvement in developmental 
stages of several cell types affected in PD. 
Numerous working models have been proposed to integrate the complexities of 
environmental, biochemical, genetic and neuropathological evidence. However, a more 
simplicistic model of PD pathogenesis depicts a progressive imbalance between the forces 
that promote degeneration of at risk neurons by increasing mitochondrial dysfunction and 
oxidative stress during the aging process, and those that encompass individual or integrated 
cellular-defense mechanism. 
Genetic therapy should move forward, aiming to restabilize the balance between these 
antagonist forces: enhancing the neuroprotective ones (PRKN, DJ-1, PINK1) and/or 
stopping and silencing potentiallty harmful effects ones (SNCA, LRRK2) 
8. Pathological mechanisms in neurodegenerative diseases 
Parkinson’s disease is a progressive neurodegenerative disease which shares genetic influences 
and pathways with other neurodegenerative diseases like Alzheimer’s disease (AD). 
Specifically, common pathways involve protein aggregation and neuroinflammatory process. 
Several lines of investigation have now converged to show that the etiologies of AD and 
PD share common mechanisms (Bossy-Wetzel et al., 2004). One of the commonalities 
between AD and PD is the extra and intracellular accumulation of protein aggregates rich 
in ┚-pleated sheet conformation, representing the hallmarks of these two slowly 
progressive neurodegenerative disorders. Such protein aggregates might arise, in part, as 
a consequence of impaired proteasomal and/or autophagic removal of the damaged 
proteins (Taylor et al., 2002; Bence et al., 2001). The conformational change that results in 
the accumulation of misfolded proteins — amyloid-┚ (A┚) and tau in AD and ┙-synuclein 
in PD — is associated with progressive dysfunction and death of cells in selected brain 
areas, determining clinical presentation. The intermediate forms of pathogenic proteins 
such as oligomers and protofibrils are thought to have cytotoxic effects on neurons. There 
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is considerable overlap in the mechanisms by which oligomeric A┚ and ┙-synuclein 
damage and kill neurons that may include: oxidative stress and free radical formation, 
impaired bioenergetics and mitochondrial dysfunction, disruption of neuronal Golgi 
apparatus and transport, molecular chaperones, neurotrophins and “neuroinflammatory” 
processes. 
While variability in several genes may influence the risk for developing one disease, single 
genes often affect the risk for more than one trait. This diversity is best exemplified by 
variability in the tau and alpha-synuclein (SNCA) proteins, which alter risk of PD (MAPT 
and SNCA), progressive sopranuclear palsy corticobasal degeneration (MAPT), and multiple 
system atrophy (SNCA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Mutations and variants in the MAPT gene, encoding for tau protein, are involved in 
several neurodegenerative diseases, tauopathies: progressive sopranuclear palsy, PSP, 
corticobasal degeneration, CBD, Alzheimer disease, AD, Als-PD-dementia complex of Guam 
and Parkinson’s disease. 
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Fig. 3. Mutations and variations in the SNCA gene, encoding for ┙-synuclein, are involved in 
several neurodegenerative diseases, synucleinopathies: Parkinson’s disease, PD, Multi 
system atrophy, MSA, Dementia with Lewy Bodies, DLB 
 
 
 
 
Fig. 4. Variations in the HLA, the major histocompatibility complex gene, are involved in 
several neurodegenerative diseases: Parkinson’s disease, PD, Alzheimer disease, AD, 
Multiple sclerosis, MS, Amiotrofic Lateral Sclerosis, ALS. 
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Fig. 5. Variations in LINGO1 and LINGO2 are risk factors for Parkinson’s disease, PD, and 
essential tremor, ET. 
 
 
 
 
 
 
 
Fig. 6. Mutations in DJ-1 can be involved in several neurodegenerative diseases: Parkinson’s 
disease, PD, dementia and Amyotrophic Lateral Sclerosis, ALS. 
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Ultimately, a joint GWA study of a pooled population of individuals with Alzheimer’s 
disease and Parkinson’s disease might be a powerful approach to identify common genetic 
susceptibility factors for these diseases. One interesting model is that tau acts as a 
downstream factor involved in both ┚-amyloid and ┙-synuclein toxicity, with 
neurofibrillary tangles only forming in the presence of amyloid. Therefore, ┚-amyloid and ┙-
synuclein might reinforce each other’s effect on neurodegeneration in the aging population, 
and the relative proportions of each pathology could correlate with the extent of dementia 
or parkinsonism, respectively. Recent studies suggest that environmental factors may 
contribute to neurodegeneration through the induction of epigenetic modifications, such as 
DNA methylation, and chromatin remodeling, which may induce alterations in gene 
expression programs. Epigenetics, which refers to any process that modifies gene activity 
without changing the actual DNA sequence, and leads to modifications that can be 
transmitted to daughter cells, is a relatively novel area of research that is currently attracting 
a high level of interest. Epigenetic modulation is present since the prenatal stages, and the 
aging process is now accepted to be associated with a loss of phenotypic plasticity to 
epigenetic modifications. Since aging is the most important risk factor for idiopathic AD and 
PD, it is expected that epigenetic alterations on DNA and/or chromatin structure may also 
accumulate during neurodegeneration, explaining to some extent the etiology of these 
chronic and progressive disorders. 
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